Key Highlights

  • Shares closed up 6.05% at $10.51, rebounding from lows near $8 in September.
  • Investors are positioning ahead of the founder's October 16 fireside chat at an oncology investor symposium.
  • The FDA is expected to decide by January 6, 2027, on expanding the company's lead product to papillary-only bladder cancer.
  • Second-quarter net product Revenue reached a record $50.7 million, up 92% year over year.
  • A research firm upgraded the stock to strong buy following the revenue report.

Speculative Buying Builds Ahead of Investor Symposium

ImmunityBio (NASDAQ:IBRX) shares closed higher, attracting speculative buying ahead of founder Patrick Soon-Shiong's fireside chat at an oncology investor symposium scheduled for October 16. ImmunityBio is a San Diego-based, commercial-stage immunotherapy company that develops next-generation therapies and vaccines to activate the innate and adaptive immune systems against cancer and infectious diseases.

Shares are rebounding from lows near $8 reached in September, with today's gain adding to a recovery that has been building ahead of the symposium appearance.

FDA Decision on Bladder Cancer Expansion Looms in January

The Food and Drug Administration is expected to decide by January 6, 2027, on expanding approval of the company's lead product, an IL-15 superagonist currently approved for a specific form of bladder cancer, to cover papillary-only bladder cancer as well. A positive decision would broaden the addressable patient population for the company's flagship immunotherapy.

Record Revenue and Analyst Upgrade Support Sentiment

Sentiment has also been helped by a record second-quarter net product revenue of $50.7 million, up 92% year over year, along with a recent upgrade to strong buy from a covering research firm. The company's founder has also committed Capital through a private Investment in a separate biotechnology company, a move some investors read as a signal of continued confidence in the broader immuno-oncology space.

Cash Position Remains a Watch Point Despite the Rally

Healthcare was also firmer on the day, adding a supportive backdrop to today's gain. Even so, heavy losses and ongoing financing needs remain a concern some investors continue to weigh, alongside elevated Treasury yields, against the bullish case built on the upcoming FDA decision and symposium appearance.